Company intelligence / Profile preview
Minerva Biotechnologies
Waltham, Massachusetts, United Statesminervabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Minerva’s lead program uses autologous CAR T cells targeting MUC1*, a marker present on ~80% of solid tumors. Early clinical data are not yet published but the company has received IND approval to begin Phase I trials with its huMNC2-CAR22 product. The company also develops antibody-drug conjugates and small molecules in preclinical stages. Its proprietary technologies have enabled licensing agreements with major institutions such as Memorial Sloan Kettering Cancer Center.
- Therapeutic areas
- OtherOncology
- Modalities
- Autologous CAR-T cell therapyAntibody-drug conjugates (ADC)Small molecule drugsBispecific antibodies (BsAb)Cell therapy/regenerative medicine
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Memorial Sloan Kettering Cancer Center – licensing agreement for “1XX” technology to enhance persistence of their anti-MUC1* CAR T therapies in patients.
Beyond the preview
Go deeper on Minerva Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minerva Biotechnologies.